GLP-1 drugs: anti-obesity treatment or genuine gerotherapeutic?
A Nature Aging perspective examined whether GLP-1 receptor agonists — drugs developed for weight and glucose management — act on aging biology broadly enough to qualify as gerotherapeutics, probing whether observed benefits in cardiovascular, renal, and metabolic outcomes reflect genuine engagement with aging mechanisms or are downstream of weight loss.